Fig. 6

NORAD facilitates the tumorigenicity of PCSCs in vivo by competitively inhibiting miR-202-5p and upregulating ANP32E. A Representative images showing xenografts in nude mice treated with miR-202-5p mimic, si-ANP32E, si-NORAD, ANP32E, NORAD, miR-202-5p mimic + ANP32E or NORAD + miR-202-5p mimic. B Tumor weight of mice treated with miR-202-5p mimic, si-ANP32E, si-NORAD, ANP32E, NORAD, miR-202-5p mimic + ANP32E or NORAD + miR-202-5p mimic. C Tumor volume of mice treated with miR-202-5p mimic, si-ANP32E, si-NORAD, ANP32E, NORAD, miR-202-5p mimic + ANP32E or NORAD + miR-202-5p mimic. * p < 0.05 vs. mice without treatment. The above results are all measurements and expressed as mean ± standard derivation. One-way analysis of variance with Tukey’s post hoc test was used for data comparison among multiple groups. Repeated measures analysis of variance was performed for data comparison at different time points with Bonferroni’s post hoc test (n = 12)